Previous Article | Next Article ![]()
Journal of Virology, September 2004, p. 9605-9611, Vol. 78, No. 18
0022-538X/04/$08.00+0 DOI: 10.1128/JVI.78.18.9605-9611.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Department of Bacteriology, Yamagata University School of Medicine, Yamagata, Japan
Received 29 February 2004/ Accepted 23 April 2004
|
|
|---|
|
|
|---|
Based on analysis of the HA sequences of A/H3N2 viruses isolated from 1968 to 2002, the oligosaccharide chains on the globular head show large variations in number among different A/H3N2 isolates, although five glycosylation sites at Asn residues 8, 22, 38, 285, and 483 on the stem region are strictly conserved. Most of the A/H3N2 viruses that circulated between 1968 and 1974 (represented by A/Aichi/2/68) had only two oligosaccharides at residues 81 and 165 on the globular head of the HA (Fig. 1A). However, viruses isolated in 1975 (represented by A/Victoria/3/75) had lost a glycosylation site at residue 81 and gained two new sites at residues 63 and 126. The 1986 isolates (represented by A/Memphis/6/86) had acquired a new carbohydrate attachment site at residue 246, and the 1997 isolates (represented by A/Sydney/5/97) had obtained two additional sites at residues 122 and 133. Some recent isolates (represented by A/Panama/2007/99) had often obtained a novel site at residue 144. Thus, the A/H3N2 viruses recently circulating have six or seven glycosylation sites on the globular head of the HA, although whether these are glycosylated is not known. Moreover, the HAs of influenza A/H1N1 viruses and influenza B viruses isolated recently also possess several oligosaccharide chains on their globular head. These observations suggest that the addition of new oligosaccharides to the globular head of the HA may provide influenza viruses with an increased ability to prevail among humans (14). Interestingly, however, examination of the available HA sequences of influenza A/H2N2 viruses showed that none of the HAs had obtained a new glycosylation site on the globular head, and they had only one carbohydrate chain at position 169 (21).
![]() View larger version (53K): [in a new window] |
FIG. 1. Schematic drawing of the globular head of influenza A/H3N2 virus HA, showing the change in N-glycosylation sites among representative isolates (A) and the mutant HAs used in this study (B). N-glycosylation sites are indicated by solid circles. Numbers indicate Asn residues in the first position of the glycosylation sequon.
|
There are several lines of evidence indicating that the number, structure, and location of the oligosaccharide chains modulate the antigenicity of the HA by masking the protein surface and that the addition of carbohydrate is more effective than a single amino acid substitution in changing the antigenic properties of the HA (2, 14, 16, 21). The failure of A/H2N2 viruses to employ this effective strategy for evading immune pressures might be one of the causes for their short survival time in humans (22).
Several studies have been carried out to analyze the effect of oligosaccharides on the properties of H3 HA. Gallagher et al. (3) reported that the addition of oligosaccharide chains at novel sites located on areas of the surface of the HA that are not normally shielded by carbohydrate affected the folding, transport, and biological activities of the molecule. However, the effect of addition of glycosylation sites, found in natural isolates during antigenic drift in A/H3N2 viruses, has never been investigated. In the present study, we constructed seven mutant HAs of A/Aichi/2/68 (H3N2) virus having one to six glycosylation sites on the globular head and expressed them in COS-1 cells. Mutant HAs with glycosylation sites as found on the HA of representative A/H3N2 isolates (A/Victoria/3/75, A/Memphis/6/86, and A/Sydney/5/97) and their intracellular transport and biological activities were analyzed. We also investigated the reactivity of mutant HAs with human sera to study whether the addition of oligosaccharide chains to the HA of A/H3N2 virus affects their antigenicity.
|
|
|---|
Antibodies. Rabbit antiserum against egg-grown A/Aichi/2/68 virions was prepared as described previously (27). Human sera were collected in 1976 from donors who were born between 1953 and 1955 and stored at 20°C until assay.
Plasmid construction and site-directed mutagenesis. The wild-type HA gene cDNA of A/Aichi/2/68 virus in a transient expression vector, pME18S (19) (pMEHA), was generously provided by K. Nakajima (Nagoya City University, Japan) (10). Mutant HA gene cDNAs encoding one to six N-glycosylation sites were generated by site-directed mutagenic PCR with mutant primers (sequences are available upon request), with pMEHA as a template (Fig. 1B). Mutant oligonucleotide primers were designed as the same consensus sequence for N-glycosylation as found in natural isolates A/Victoria/3/75, A/Memphis/6/86, and A/Sydney/5/97. The Thr at position 83 was replaced with Lys to eliminate a glycosylation site at position 81. The Asp, Thr, Asn, and Gly at positions 63, 126, 135, and 248 were changed into Asn, Asn, Thr, and Thr, respectively, to create a carbohydrate addition site at positions 63, 126, 133, and 246, respectively. Moreover, the Thr and Gly at positions 122 and 124 were replaced by Asn and Ser, respectively, to create a glycosylation site at position 122.
The PCR products were excised by digestion with BclI and XhoI, and the resulting DNA fragments were subcloned into the BclI and XhoI sites of pMEHA. Each mutant HA was generated with the previous one as a template. G3, G4, and G6 had the same consensus sequences for glycosylation as the natural isolates A/Victoria/3/75, A/Memphis/6/86, and A/Sydney/5/97, respectively. The nucleotide sequences of all mutant cDNAs in pME18S plasmids were confirmed by cycle sequencing with the BigDye terminator cycle sequencing FS ready reaction kit (Applied Biosystems) and an ABI Prism 310 automatic sequencer (Applied Biosystems).
Transfection, radioisotopic labeling, and immunoprecipitation. Subconfluent monolayers of COS-1 cells in 3.5-cm petri dishes were transfected with 1 µg of the recombinant pME18S plasmid containing a wild-type or mutant HA gene with Lipofectamine Plus (Invitrogen) according to the manufacturer's instructions. At 48 h posttransfection, cells were labeled for 15 min with 10 µCi of [35S]methionine (ARC) per ml in methionine-deficient DMEM. Cells were then disrupted in 0.01 M Tris-HCl (pH 7.4) containing 1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.15 M NaCl, and a cocktail of protease inhibitors (5) and immunoprecipitated as described previously (17) with rabbit antiviral serum or human serum. The immunoprecipitates obtained were analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) on 13% gels (unless otherwise noted) containing 4 M urea under reducing conditions.
Endoglycosidase H digestion. Transfected COS-1 cells were labeled with [35S]methionine for 20 min at 48 h posttransfection and chased for 4 h in DMEM containing 1 mM nonradioactive methionine. Cells were then immunoprecipitated with rabbit antiviral serum, and the immunoprecipitated proteins were digested with endoglycosidase H (30 mU) for 16 h at 37°C under the conditions described previously (5), precipitated with acetone, and analyzed by SDS-PAGE.
Trypsin treatment of transfected cells. At 48 h posttransfection, transfected COS-1 cells were labeled with [35S]methionine for 20 min and chased for 4 h. During the last 15 min of the chase, cells were treated with DMEM containing 5 µg of tosylsulfonyl phenylalanyl chloromethyl ketone (TPCK)-trypsin per ml, and the reaction was terminated by addition of soybean trypsin inhibitor. Cells were then immunoprecipitated with rabbit antiviral serum, and the resulting immunoprecipitates were analyzed by SDS-PAGE on 17.5% gels.
Hemadsorption test. Transfected COS-1 cells were washed once with DMEM at 48 h posttransfection, followed by incubation with 5 mU of Arthrobacter ureafaciens neuraminidase per ml (Roche Diagnostics) at 37°C for 1 h. Cells were then washed three times with DMEM and incubated at room temperature for 10 min with a 1% suspension of guinea pig erythrocytes or a 0.5% suspension of chicken erythrocytes. The monolayers were then washed several times with phosphate-buffered saline (pH 7.4) lacking Ca2+ and Mg2+ and examined by phase contrast microscopy. For quantification of the extent of hemadsorption, erythrocytes were lysed in 1 ml of distilled water. After removal of cellular debris by low-speed centrifugation, the released hemoglobin in the supernatant was measured by reading the absorption at 540 nm.
Cell fusion assay. At 48 h posttransfection, transfected COS-1 cells were treated with 5 µg of TPCK-trypsin per ml in DMEM for 15 min at 37°C and then exposed to the warm fusion medium (phosphate-buffered saline with 10 mM morpholineethanesulfonic acid and 10 mM HEPES adjusted to pH 5.0) for 5 min. The fusion medium was then replaced with neutral DMEM containing 10% fetal calf serum, and the cells were incubated at 37°C for 3 h. The cells were then fixed with methanol and stained with Giemsa solution.
|
|
|---|
![]() View larger version (30K): [in a new window] |
FIG. 2. Expression of mutant HAs. COS-1 cells transfected with wild-type (WT) or mutated HA gene cDNA were labeled with [35S]methionine for 15 min at 48 h posttransfection in the absence (TM) or presence (TM+) of tunicamycin. Cells were then immunoprecipitated with antiserum against A/Aichi/2/68 virus, and the resulting immunoprecipitates were analyzed by SDS-PAGE. HANG, nonglycosylated HA. The arrowhead indicates the coprecipitated endoplasmic reticulum-resident chaperone binding protein BiP.
|
|
View this table: [in a new window] |
TABLE 1. Biological activities of mutant HAs
|
![]() View larger version (36K): [in a new window] |
FIG. 3. Intracellular transport of mutant HAs. COS-1 cells expressing wild-type (WT) or mutant HA were labeled with [35S]methionine for 20 min at 48 h posttransfection and chased for 4 h. (A) Immediately after a pulse (P) or after a subsequent chase (C), cells were immunoprecipitated with antiserum against A/Aichi/2/68 virus. The resulting precipitates were digested (+) or mock digested () with endoglycosidase H and analyzed by SDS-PAGE. R and S indicate the endoglycosidase H-resistant and -sensitive forms of HA, respectively. (B) Cells were treated (+) or not () with TPCK-trypsin during the last 15 min of the chase and then immunoprecipitated with antiserum against A/Aichi/2/68 virus. The resulting immunoprecipitates were analyzed by SDS-PAGE on 17.5% gels.
|
Biological activities of mutant HAs. In order to investigate the effect of addition of new oligosaccharides to the globular head of H3 HA on its receptor binding activity, COS-1 cells transfected with the wild-type or one of the mutant HA genes were treated with neuraminidase at 48 h posttransfection and examined for hemadsorption according to the procedures described in Materials and Methods. The amounts of wild-type and mutant HAs expressed in transfected cells were determined by measuring the radioactivity of the HA bands after SDS-PAGE of [35S]methionine-labeled cell lysates, and the expression levels of all the mutant HAs were comparable to that of wild-type HA (data not shown). The extent of hemadsorption was enhanced significantly by neuraminidase treatment (data not shown), as has been observed with the HAs of H7, H1, and H2 viruses (11, 22). When the hemadsorption assays were done with guinea pig erythrocytes, little difference was observed in the extent of hemadsorption among wild-type HA from the G1, G2, and G3 mutants (Fig. 4A). When chicken erythrocytes were used for the assays, the hemadsorbing activities of G1 and G2 were similar to that of wild-type HA (Fig. 4B). By contrast, G4, G5a, G5b, and G6 exhibited a significant decrease (3 to 25% of the level with wild-type HA) in the extent of hemadsorption with both types of erythrocytes (Table 1), indicating that mutant HAs containing four to five oligosaccharide chains had drastically decreased receptor binding activity.
![]() View larger version (20K): [in a new window] |
FIG. 4. Receptor binding activity of mutant HAs. COS-1 cells were transfected with cDNA encoding wild-type (WT) or mutant HA protein. At 48 h posttransfection, cells were subjected to hemadsorption with guinea pig erythrocytes (A) or chicken erythrocytes (B). Erythrocytes that attached to the HA-expressing cells were lysed in distilled water, and the amounts of hemoglobin released were measured by reading the absorption at 540 nm and are shown as a percentage of the wild-type HA value.
|
![]() View larger version (137K): [in a new window] |
FIG. 5. Cell fusion activity of mutant HAs. COS-1 cells expressing wild-type (WT) or mutant HA were treated with TPCK-trypsin at 48 h posttransfection, exposed to fusion medium (pH 5.0), and then incubated for 3 h in neutral-pH medium. At the end of the incubation period, the cells were stained with Giemsa solution.
|
The immunoprecipitates obtained were subjected to SDS-PAGE (Fig. 6A). The expression levels of all the mutant HAs were comparable to that of wild-type HA as described above. The radioactivity of the HA bands after SDS-PAGE of immunoprecipitates was measured, and the values obtained were used to calculate the relative specific reactivity with human sera (Fig. 6B). A representative result with a serum for which the hemagglutination inhibition titer against A/Aichi/2/68 virus was 160 HIU/ml is shown in Fig. 6A. The reactivity of G1 with most of the human sera tested was slightly higher than that of wild-type HA. However, the reactivity of G2 and G3 was slightly lower than that of wild-type HA, and the reactivity of G4, G5a, G5b, and G6 was reduced by 57 to 75% compared with that of wild-type HA. These observations raised the possibility that the addition of four to five oligosaccharide chains considerably affects the antigenicity of the HA molecule.
![]() View larger version (30K): [in a new window] |
FIG. 6. Reactivity of mutant HAs with human sera. COS-1 cells transfected with wild-type (WT) or mutated HA gene cDNA were labeled with [35S]methionine for 15 min at 48 h posttransfection. The cells were then immunoprecipitated separately with six human sera collected in 1976 which had hemagglutination inhibition activity against A/Aichi/2/68 virus (160 HIU/ml) but not against A/Victoria/3/75 virus (<10 HIU/ml) or A/Sydney/5/97 virus (<10 HIU/ml). The immunoprecipitates obtained were subjected to SDS-PAGE (A), and the radioactivity of the HA bands was measured (B). The relative specific reactivity of the mutant HAs was determined as a percentage of that of wild-type HA. The solid line shows the average for the six sera.
|
|
|
|---|
We previously investigated the impact of carbohydrate addition to novel sites located on the tip of H2 HA on reactivity with human sera (22). The results indicated that H2 HA with additional oligosaccharides at two or three of positions 131, 160, and 187 displayed markedly decreased reactivity with human sera. In this study, we showed that the addition of oligosaccharide chains to the globular head of H3 HA resulted in a decrease in reactivity with human sera compared with wild-type HA, as was observed with H2 HA. Therefore, the data obtained here suggest that the addition of new oligosaccharides to the globular head of the HA of A/H3N2 viruses affected the antigenicity of the molecule and may have provided the viruses with the ability to evade antibody pressures. The mutant HAs that acquired an additional oligosaccharide chain at Asn residue 246 showed drastically reduced receptor binding activity and reactivity with human sera. These observations raised the possibility that carbohydrate addition to position 246 is critical for the receptor binding activity and antigenicity of the HA of A/H3N2 virus. To confirm this notion, experiments to examine the role of individual oligosaccharide chain are in progress.
Mutant G1 had only one oligosaccharide chain at position 165 on the globular head because the glycosylation site at position 81 was removed. Previously, Gallagher et al. (4) and Nakajima et al. (8) analyzed similar mutant HAs of A/Aichi/2/68 virus which had the same glycosylation sites as in G1. Although the mutated consensus sequences for glycosylation at position 81 were different from each other, all of these mutant HAs were transported to the cell surface and had wild-type receptor binding activity and cell fusion activity. These observations suggest that the removal of an oligosaccharide chain at position 81 does not affect the intracellular transport and biological activities of H3 HA.
Comparison of electrophoretic mobility between the wild-type and mutant HAs showed that four introduced glycosylation sites at Asn residues 63, 126, 133, and 246 were used. G5a and G6 had four (positions 63, 126, 246, and 122) and five (positions 63, 126, 133, 246, and 122) introduced sites, respectively. One glycosylation site on each of G5a and G6 was not glycosylated, although it remains unclear which carbohydrate attachment site was not used for glycosylation. The electrophoretic mobility of HA of A/Sydney/5/97 virus, which had the same glycosylation sites as G6, was increased compared with that of G6 when proteins synthesized in the presence of tunicamycin were analyzed (data not shown). However, A/Sydney/5/97 virus HA synthesized in the absence of tunicamycin displayed a slightly slower mobility than G6. Therefore, it is reasonable to conclude that, in contrast to G6, all of the glycosylation sites on the HA of A/Sydney/5/97 virus are used.
Since the oligosaccharide attachment sites of G6 were introduced into the HA of A/Aichi/2/68 virus as a template, distortion of the HA structure caused by amino acid substitutions between A/Aichi/2/68 virus and A/Sydney/5/97 virus might have occurred, resulting in the failure of G6 to acquire oligosaccharide chains at all of the potential glycosylation sites. Two carbohydrates at positions 122 and 126 are located close to each other, so that glycosylation at either of these positions may be impossible because of steric hindrance by an oligosaccharide attached to an asparagine in the neighborhood (7, 25).
After the 1992 and 1993 seasons, human influenza A/H3N2 viruses isolated in MDCK cells did not agglutinate chicken erythrocytes but did agglutinate human and goose erythrocytes (10). Nobusawa et al. (10) reported that a change in amino acid residue 190 from Glu to Asp was responsible for this characteristic, as determined in studies with HA cDNA of A/Aichi/51/92 virus. Nakajima et al. (8) demonstrated that an amino acid change from Glu to Asp at residue 190 of A/Aichi/2/68 virus HA did not inhibit its hemadsorbing activity with chicken erythrocytes. Therefore, they suggested that multiple amino acid substitutions on the HA of A/Aichi/2/68 virus are necessary to change the receptor specificity. The present study raised the possibility that the increase in the number of oligosaccharide chains on the globular head of H3 HA might be one of the causes for the failure of recent A/H3N2 viruses to agglutinate chicken erythrocytes. However, our mutant HAs exhibited reduced hemadsorbing activities not only with chicken erythrocytes but also with human, goose, sheep, and turkey erythrocytes (data not shown). Therefore, it seems likely that the inability of recent A/H3N2 viruses to agglutinate chicken erythrocytes might not be related to additional oligosaccharides.
The A/Aichi/2/68 strain, known to preferentially bind to sialic acid in the
2,6Gal linkage rather than the
2,3Gal linkage on erythrocytes, agglutinated chicken, guinea pig, human, and duck erythrocytes (6). Mutant G3 exhibited a decrease in the extent of hemadsorption with chicken erythrocytes (36% of wild-type HA), although its hemadsorbing activity with guinea pig erythrocytes was comparable to that of wild-type HA. These observations suggest that the guinea pig erythrocytes have higher levels of sialic acid in the
2,6Gal linkage than do chicken erythrocytes, which may explain why G3 binds guinea pig erythrocytes better.
This paper is dedicated to Kiyoto Nakamura, who passed away on 20 October 2001. ![]()
|
|
|---|
promoter: an efficient and versatile mammalian cDNA expression system composed of the simian virus 40 early promoter and the R-U5 segment of human T-cell leukemia virus type 1 long terminal repeat. Mol. Cell. Biol. 8:466-472.
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»